Press Releases

Biosign is a medical device company. Our products include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The company is publicly listed on the TSX - Venture Exchange (TSX-V:BIO). We have been a listed company since July 14, 2006. Our auditors are Collins Barrow LLP and our corporate filings are available on SEDAR.

January 26 2012	Biosign and EasyMed Sign Distribution Agreements and Development and License Agreement Biosign Technologies Inc. (TSXV: BIO) ("Biosign") and EasyMed Services, Inc. (CNSX: EZM) (OTCBB: EMYSF) ("EasyMed") are pleased to announce they have executed agreements that allow the resale and distribution of each other's respective products as well as a Development and License Agreement for the creation of a joint product offering.
December 5 2011	Biosign and EasyMed Sign LOI to Collaborate on Mobile Health Offering Mobile Health (mHealth), an area of electronic health (eHealth), is the provisioning of health services and information via mobile technologies such as mobile phones, Personal Digital Assistants (PDAs) and smartphones. According to Research & Market 2009's "U.S. Healthcare IT Market Analysis" study, the American mobile health market is estimated to be worth $2.1 billion at the end of 2011 and is expected to grow with a CAGR of nearly 22% from 2012 to 2014. Providing patient facing solutions for healthcare providers and payers is anticipated to open significant underserviced markets for both Biosign and EasyMed's products.
November 28 2011	Q3 2011 Interim Financial Statements Biosign releases Q3 2011 interim finanial statements.
November 28 2011	Q3 2011 Management Discussion and Analysis Biosign releases Q3 2011 management discussion and analysis.
November 15 2011	Biosign Technologies Updates Bay Street Connect IR Services Terms and Contact Information Biosign announces the monthly terms of the agreement reached with Bay Street Connect whereby the latter will provide Biosign with investor relations and financial communications services. Bay Street Connect, a Toronto-based company owned by its employees, provides communications services to Canadian public companies. The service contract is anticipated to cost $7,500 per month and is for an initial term of twelve months and may be terminated on 30-day notice.
November 14 2011	Biosign Technologies Retains IR Firm Bay Street Connect and Grant of Stock Options Biosign is pleased to announce that it has retained Bay Street Connect to provide Biosign with financial communications and investor relations services for up to one year. The service contract with Bay Street Connect, a Toronto-based company that provides communications services to public Canadian companies, will focus on positioning Biosign with the investment community, market analysts and company stakeholders.
November 10 2011	Biosign Develops Algorithm for use in Pre-Screening for Arrhythmia Biosign focused on non-invasive monitoring of common health risks associated with blood pressure, life style and medication, is pleased to announce they have developed proprietary algorithms that can be utilized on the UFIT generated pulse waveform as a prescreening tool for arrhythmia.
November 3 2011	Biosign Corporate Update Biosign announced today that it has shifted its near term corporate strategy from a focus on R&D associated with the commercialization of the UFIT TEN-20 non-invasive blood pressure and blood glucose meter towards cash generation activities from the sale of the UFIT TEN-10 blood pressure monitor.
October 5 2011	Biosign Names New Board Chair and Audit Committee Member Biosign announced the appointment of Jason D. Meretsky as chairman of its board of directors. The company also announced the appointment of Harold Koplewicz to the audit committee and the resignation of Dr. David Silver from his position as chair and as a member of the board of directors.
September 27 2011	Biosign CEO Demonstrates Cloud Dx(TM) Solution at Health 2.0 Conference Biosign sponsored the "In Conversation with 3 CEO's" panel featuring Anne Wojcicki of 23andme, Sona Mehring of Caring Bridge, and West Shell of Healthline at the Health 2.0 Conference. Biosign, CEO, Dr. Scott Jenkins is scheduled to introduce the panel to over 1,000 attendees and demonstrate the Cloud DxTM solution that enables providers to deliver quality care utilizing the UFIT® device and remote cloud monitoring systems.
September 26 2011	Biosign Offers Non-Invasive Glucose Testing at Health 2.0 Conference to Attendees Biosign will be offering a free non-invasive glucose testing demonstration during the Health 2.0 conference being held in San Francisco today and tomorrow.
September 26 2011	Biosign Technologies Expands Strategic Alliance with HealthSaas to include Cloud Dx Solution Biosign has announced an expansion of their strategic alliance with HealthSaaS, Inc to add the Cloud DxTM solution and non-invasive blood glucose measurements to the HealthSaaS Connected Outcomes Framework®.
September 19 2011	Biosign Response to Annual Shareholder Meeting Questions Biosign held its annual shareholders meeting last week. All matters of business as described in the Information Circular were approved, including the election of Steven Bloom to the Board of Directors and the ratification of the company's employee stock option plan.
September 14 2011	Biosign Technologies Annual Shareholders Meeting Presentation Dr. Scott Jenkins, CEO of Biosign Technologies, presents to the attending shareholders the direction of the company.
September 8 2011	Cloud Dx Sponsors CEO Panel at Health 2.0 Conference Cloud Dx, a division of Biosign, is proud to be the sponsor of the "In Conversation with 3 CEO's" panel at the Health 2.0 Conference.
August 17 2011	Annual General Meeting of Shareholders, to be held September 12, 2011 Biosign announced that the Annual General Meeting of shareholders of Biosign Technologies Inc. will be held at the office of Goodmans LLP, Suite 3400, Bay Adelaide Centre, 333 Bay Street, Toronto, Ontario, on September 12, 2011 at 11:00 a.m. (Toronto time). <a href="http://biosign.com/docs/tsxv-bio_agm_2011.zip">Download the related documents</a>
July 27 2011	Biosign Completes Brokered Private Placement Biosign closed a brokered private placement of units of the Company for gross proceeds of approximately $1,900,000. A total of 2,384,551 units were issued at a price of $0.80 per Unit. Each Unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant will entitle the holder to purchase one common share of the Company at a price of $1.00 for a period of 12 months from closing date, subject to an acceleration of the expiry date, upon requisite board notice, in the event the price of the common shares on the TSX Venture Exchange closes in excess of $1.50 for five consecutive trading days.
June 22 2011	Biosign Grant of Stock Options Biosign granted an aggregate of 3,115,000 stock options pursuant to the Company's stock option plan to four directors of the Company and to Dr. Scott Jenkins in connection with his appointment as Chief Executive Officer of the Company. These options expire in 5 years, have an exercise price of $0.92 per share.
June 22 2011	Dr. Scott Jenkins Appointed CEO Most recently, Dr. Jenkins was the Vice President of Worldwide Solution Sales at DELL Healthcare and Life Sciences, where he was directly responsible for managing over 500 channel solution partners. Previously, Dr. Jenkins has held various senior positions with, Applied Biosystems, IBM Healthcare & Life Sciences, and Apple.
May 27 2011	Three New Biosign Board Members Biosign has nominated three new directors: Dr. Harold S. Koplewicz, Jason D. Meretsky, and Former Senator Alfonse D'Amato.
May 12 2011	Biosign announces UFIT health monitoring study Initiation of a short-term study of the UFIT biomedical system to determine the best practices for monitoring blood pressure and blood glucose. The study is being conducted in collaboration with McMaster University.
May 3 2011	Biosign Provides Corporate Update Biosign provided a corporate update today, subsequent to reporting its financial and operating results to SEDAR for the fiscal year ended December 31, 2010. The company's audited financial statements and Management's Discussion and Analysis are available at www.sedar.com
April 25 2011	Colley Clarke appointed CFO of Biosign Technologies Colley Clarke has been named CFO on an interim basis. Mr. Clarke is known for his financial leadership of TSX Venture Exchange and NASDAQ listed companies. He will oversee Biosign's finance, accounting and investor relations functions, while focusing on the company's growth and profitability
April 19 2011	Biosign Director Resigns, CEO Relieved of Duties During a scheduled meeting yesterday, Biosign's board of directors has accepted the resignation of Alfonse D'Amato as director of the company, relieved Peter Tassiopoulos of his duties as CEO, and resolved to start searching for a new chief executive. Radu Leca, Biosign's President, has been named CEO on an interim basis.
March 23 2011	Dell and Biosign Technologies Enter into Global Hosting Agreement... Dell will offer Biosign a fully-integrated, end-to-end solution that includes hardware, data center hosting and support.
March 16 2011	Biosign and Peconic Bay Medical Center Sign Agreement to Implement Healthanywhere Remote Patient Management Program Under this agreement, Peconic will use Biosign's Healthanywhere to provide a sustainable "Health at Home" solution for short-term remote monitoring of post-discharge patients with a baseline of vital signs for participating patients.
February 10 2011	bioAnalytics' HeartFriendly Dentist Program Gathers Momentum bioAnalytics Inc. has installed the Biosign's UFIT® system in thirty operatories in less than thirty days since introduction. The first five Dental Clinics to utilize UFIT® under the HeartFriendly(TM) Dentist program are seeing the benefits of the program.
February 7 2011	Biosign Master Distributor ALQAEM Increases Initial UFIT Order by 150% The Health Care Division of ALQAEM International FZE has increased their initial order for Biosign's pulse acquisition devices (UFIT® PAD) to 500,000 USD. Biosign plans to start shipping UFIT® to the MENA region this quarter. Under the terms of the Exclusive Master Distributor Agreement between Biosign and ALQAEM, this initial order should generate, once fully deployed, an annual recurring revenue for Biosign in excess of 2 million USD.
February 1 2011	Scott Worthington Appointed CFO of Biosign Mr. Worthington has over 30 years of senior financial and executive management experience, including 9 years at Dell Computer Corporation, where he held numerous positions including Chief Financial Officer of the Canadian subsidiary.
January 24 2011	Biosign and ALQAEM introduce UFIT at the Arab Health Congress in Dubai Biosign and ALQAEM will be exhibiting at booth S1G61 during the Congress, which is the largest healthcare exhibition in the Middle East and the second largest healthcare event of this type in the world.
January 21 2011	bioAnalytics launches HeartFriendly Dentist Program with the Dental Health Group of Burlington Using Biosign UFIT Health Monitor The HeartFriendly Dentist program represents a substantial opportunity for us to introduce Biosign's UFIT services to over 65,000 dental professionals and to the 23 million Canadians that consult them annually.
January 10 2011	Peter Tassiopoulos Appointed CEO of Biosign Chief Operating Officer, Peter Tassiopoulos, will succeed Radu Leca as Chief Executive Officer effective today. The announcement finalizes a transition process that has been planned for several months. The appointment was proposed by Dr. Leca and unanimously adopted by the Board of Directors. Dr. Leca will continue to serve as the President of Biosign.
November 10 2010	Biosign and Mitel Sign Memorandum of Understanding Biosign and Mitel have signed a Memorandum of Understanding for integrating Biosign UFIT® devices and Mitel IP telephony appliances, intended to address healthcare, pharmaceutical, and enterprise markets.
November 6 2010	Biosign Completes Financing Biosign has completed a non-brokered private placement of units of the Company for $1.25 per unit for gross proceeds of $2,300,000.
October 21 2010	Biosign Closes Acquisition of Healthanywhere Assets Biosign has completed the acquisition of substantially all of the assets of Healthanywhere Inc., a privately-held, Ontario-based, eHealth solutions company.
October 12 2010	Biosign and We Care announce results from Re-ACT program The Remote Access to Care Technology (Re-ACT) program is an Aging at Home initiative that is funded by the North Simcoe Muskoka Local (NSM) Health Integration Network and supported by a partnership with NSM Community Care Access Centre, We Care Home Health Services, and Biosign utilizing the Healthanywhere solution.
October 4 2010	Biosign to Acquire Assets of Healthanywhere Inc. Biosign has signed a binding letter of intent to purchase assets of Healthanywhere, a privately held eHealth solutions provider..
September 9 2010	Biosign Receives Approval for TSXV Biosign Technologies Inc. announces that its common shares will commence trading on the TSX Venture Exchange on September 10, 2010 under the trading symbol "BIO".
August 27 2010	Biosign Receives Conditional Approval for Listing on TSX Venture Exchange Biosign Technologies Inc. today announced that the Company has filed, on SEDAR, its Listing Statement following the receipt of the TSX Venture Exchange's (the "Exchange") conditional approval for the listing of the Company's securities.
August 19 2010	Biosign Master Distributor closes first major sale Biosign Technologies announces that ALQAEM International, its exclusive master distributor for the Middle East and North Africa Region, has placed an initial order of 2,000 Biosign UFIT® Ten-20 non-invasive glucometer devices.
August 16 2010	Biosign to Provide UFIT Services at HealthAchieve Biosign will provide conference and exhibit attendees with a blood pressure reading using UFIT®, an automated wrist blood pressure monitor with computer controls. Biosign's UFIT® system is being advanced to serve as a telematic health information system for personal monitoring and incident reporting.
August 5 2010	Biosign Engages the Trout Group for IR Services The Trout Group will provide investor relations and advisory services for Biosign effective August 6 2010. The term of the initial engagement is for one year.
July 28 2010	Biosign, ADL to Monitor Adverse Drug Reactions Biosign Technologies and ADL Data Inc. announced that they will integrate Biosign's UFIT-based system for monitoring Cardio-Hemodynamic Adverse Response to Medication with ADL's robust suite of Electronic Medical Record applications for delivery to skilled nursing homes and visiting nurse organizations.
July 22 2010	Biosign Appoints Former US Senator D'Amato Biosign Technologies Inc. announces the appointment of Former Senator Alfonse D'Amato to the Board of Directors of the Company.
July 15 2010	Biosign Applies for TSX-V Listing Biosign Technologies Inc. today announced it has made application to list its outstanding common shares on the TSX Venture Exchange. Currently, Biosign's common shares are traded on the Canadian National Stock Exchange (CNSX).
July 13 2010	Biosign and McMaster Technical Collaboration A technical collaboration announced today between Biosign Technologies Inc. (CNSX: BIO) and McMaster University will use Biosign technology to benchmark a framework for providing trusted health information services...
July 9 2010	Biosign signs Distribution Agreement for Canada Biosign Technologies Inc. and DLF Solutions Inc. (DLF), announced today they have successfully concluded negotiations resulting in an exclusive Master Distribution Agreement for the Canadian marketplace...
July 7 2010	Biosign Signs Distribution for Middle East & North Under the terms of the agreement, ALQAEM has paid an initial fee of US$100,000. Assuming local approvals are granted by the end of 2010, ALQAEM has made a commitment to achieve sales in excess of US$14 million in...
July 2 2010	Biosign Signs European Distribution Agreement Biosign Technologies Inc. today announced the signing of an exclusive Master Distribution Agreement with Swiss-based DynamiCARE AG to distribute the Biosign products in Switzerland, Germany, France, and Austria, with an option to...
June 30 2010	Biosign Expands Management with USA Team, Office Biosign Technologies Inc. is pleased to announce it has retained the services of the following individuals to execute the Company's sales and marketing objectives in the Unites States of America (US) and internationally...
June 30 2010	Biosign Acquires Assets of Cloud Diagnostics Biosign Technologies Inc. and Cloud Diagnostics LLC, today announced they have signed an Asset Purchase Agreement under which Biosign will acquire substantially all of the assets of Cloud...
June 29 2010	Biosign Reports Annual General Meeting Results Biosign Technologies Inc. reports the results of Annual General and Special Shareholder Meeting ("AGM") held on June 28th, 2010...
May 19 2010	Biosign Signs Agreement with Dental BioAnalytics Biosign Technologies Inc. and Dental BioAnalytics today announced they have signed an exclusive Reseller Agreement to sell Biosign products in the dental market segment in Canada...
May 18 2010	Biosign Enters Technical Partnership with AIM Auto Biosign Technologies Inc. and AIM Autosport announced today a multi-year technical partnership for enhancing driver performance and safety in the motor sport industry...
April 26 2010	Barrie Athletic Club to use UFIT Monitoring System Biosign Technologies Inc. and Barrie Athletic Club today announced they have signed an Agreement to utilize UFIT® monitors in assessing and refining BAC health and fitness programs as well as to sell Biosign products and...
April 22 2010	Biosign Closes Brokered Private Placement Biosign Technologies Inc. announced today the successful closing of the brokered private placement announced on March 2, 2010 and amended on April 8, 2010, for gross proceeds of...
April 16 2010	Biosign Signs Master Distribution Agreement Biosign Technologies Inc. and DLF Solutions Inc., today announced they have signed a binding Heads of Agreement to enter into a Master Distribution Agreement to distribute Biosign products in Canada through...
April 8 2010	Biosign Revises Terms of Private Placement Biosign Technologies Inc. today announced that it has revised the terms of the private placement financing announced on March 2, 2010. The Company intends to raise gross proceeds of up to...
March 17 2010	Biosign Receives NexgenRx Reimbursement Approval Biosign Technologies Inc. today announced it has received notification that NexgenRx will include Biosign's UFIT® device and services into their Benefits Plans for reimbursement according to regulatory clearances in the...
March 2 2010	Biosign Announces Private Placement Biosign Technologies Inc. today announced that it intends to raise gross proceeds of up to CDN $4.5 million through a brokered private placement of common shares of the Company at a price of...
February 11 2010	Biosign certified for non-invasive glucometry Biosign Technologies Inc. today announced it has been assessed and certified as meeting the requirements of ISO 9001:2008, ISO 13485-2003, and Directive 93/42/EEC ("CE Mark") for automated wrist blood pressure and blood glucose monitors with computer controls...
February 8 2010	Biosign Earns Microsoft Certified Partner Status Biosign Technologies Inc. today announced it has earned Certified Partner status in the Microsoft Partner Program, which recognizes Biosign's expertise and impact in the technology marketplace. Microsoft Certified Partners receive a rich set of benefits, including...